Every 10-Q that Atara Biotherape (ATRA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ATRA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ATRA filings page.
Atara Biotherapeutics, Inc. reported second‑quarter 2026 commercialization revenue of $0.6 million, down sharply from $17.6 million a year earlier, primarily reflecting the prior‑year recognition of large Pierre Fabre milestone and service amounts. For the six months, revenue was $1.1 million versus $115.7 million in the prior‑year period.
The company posted a Q2 2026 net loss of $4.8 million and a six‑month net loss of $9.0 million, compared with net income of $2.4 million and $40.4 million in the respective 2025 periods. Operating expenses fell substantially as development, manufacturing, clinical and regulatory responsibilities for tab‑cel (Ebvallo) were transitioned to partner Pierre Fabre, which now funds these activities worldwide.
At June 30, 2026, Atara had $3.2 million in cash and cash equivalents and $6.7 million in short‑term investments, total assets of $21.0 million, total liabilities of $58.0 million, and a stockholders’ deficit of $37.0 million. Management concluded that substantial doubt exists about the company’s ability to continue as a going concern for at least 12 months, citing limited liquidity and the need for additional financing or strategic transactions. The company continues to earn commercialization revenue and retains rights to significant potential regulatory and commercial milestones and double‑digit tiered royalties on future global tab‑cel sales, though many of these payments are shared with HCRx under a sale‑of‑future‑revenues arrangement.
Atara Biotherapeutics, Inc. reported Q1 2026 commercialization revenue of $516,000, sharply lower than $98.1 million a year earlier, when large milestone payments were recognized. The company posted a net loss of $4.1 million, compared with net income of $38.0 million in Q1 2025.
Total assets were $20.0 million and cash and cash equivalents were $8.4 million as of March 31, 2026. Total liabilities were $57.3 million, including $41.5 million related to the sale of future Ebvallo revenues, resulting in a stockholders’ deficit of $37.3 million.
The company states that existing cash and investments will not fund planned operations for 12 months after issuance of these financial statements and concludes that substantial doubt exists about its ability to continue as a going concern. Management plans to seek additional capital, potentially through equity offerings, debt, its ATM program, and strategic transactions, while continuing to rely on Pierre Fabre for global development, manufacturing and commercialization of tab-cel/Ebvallo. Outstanding common shares were 9,010,172 as of May 8, 2026.
Atara Biotherapeutics (ATRA) reported Q3 2025 results marked by lower revenue and a smaller operating footprint after transferring tab-cel responsibilities to Pierre Fabre. Commercialization revenue was $3.5 million, with a net loss of $4.3 million and loss from operations of $3.6 million.
Liquidity narrowed: cash and cash equivalents were $5.7 million and short‑term investments $8.0 million at September 30, 2025. Total assets were $30.2 million against total liabilities of $66.8 million, leaving a stockholders’ deficit of $36.6 million. Deferred revenue declined to $1.0 million as the company recognized prior amounts tied to its Pierre Fabre agreements.
Management concluded that substantial doubt exists about the company’s ability to continue as a going concern and outlined plans to seek additional capital, including equity facilities, debt, and strategic transactions. During 2025, Atara completed the transfer of manufacturing, clinical, development, and regulatory responsibilities for tab‑cel to Pierre Fabre. The company noted the tab‑cel BLA is tracking toward a PDUFA target action date of January 10, 2026. Shares outstanding were 7,210,235 as of November 6, 2025.
Atara Biotherapeutics (ATRA) reported a pronounced change in its mid‑2025 financial position driven by transactions with Pierre Fabre and cost reductions. Total assets declined to $36.9 million at June 30, 2025 from $109.1 million at year‑end, and cash and cash equivalents were $16.9 million. Total liabilities fell to $71.9 million, and stockholders’ deficit improved to $(35.0) million.
Commercialization revenue for the six months ended June 30, 2025 was $115.7 million, reflecting recognition of deferred revenue tied to the transfer of manufacturing, inventory and related services to Pierre Fabre; deferred revenue declined from $95.1 million at year‑end to $1.6 million at June 30. Net income for the six months was $40.4 million versus a loss of $50.8 million a year earlier, producing basic earnings per share of $3.52 for the period. The company recorded restructuring charges of $11.3 million and a lease right‑of‑use impairment of $4.1 million. Management discloses substantial doubt about the company’s ability to continue as a going concern and plans to seek additional capital.